BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Short-term Debt
Borrowings and the current portion of long-term debt due within one year.
BioAge Labs, Inc.NASDAQ: BIOA
Short-term Debt · Q1 FY2026 · quarter ended Mar 2026
Short-term debt falls 80.7% from a year ago
Short-term debt stood at $1.16M at the end of Q1 FY2026, down 80.7% from a year earlier and down 56.2% from the prior quarter. Over 3 fiscal years it compounded at +151.2% a year.
Context
- Short-term debt amounted to 0.3% of total assets at the end of Q1 FY2026, down 1.5 pp from a year earlier.
- Short-term debt increased in 1 of the last 3 fiscal years.
What to watch
Whether short-term debt keeps falling in the next quarterly balance sheet after a -80.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Debt history
USD · from the balance sheet
- Latest · FY2025
- 2.65M USD
- Year-over-year change
- -55.9%
- 3-year CAGR
- +151.2%
| Period | Period end | Short-term Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.65M | -55.9% |
| FY2024 | 2024-12-31 | 6M | -86.6% |
| FY2023 | 2023-12-31 | 44.86M | +26760.5% |
| FY2022 | 2022-12-31 | 167K | — |
Short-term Debt vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so short-term debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -80.7% is the lowest of 3, against a peer median of +101.4%.
- Short-term debt amounts to 0.3% of total assets for BIOA, versus a peer median of 1.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $23.12M USD | — | — | 15.6% | |
| Mar 2026 | CA$16.24M CAD | +281.3% | -65.6% | 1.5% | |
| Mar 2026 | $14.2M USD | — | — | 9.5% | |
| Mar 2026 | $8.42M USD | — | — | 2.1% | |
| Mar 2026 | CA$5.74M CAD | -78.5% | -66.1% | 1.0% | |
| Mar 2026 | $1.92M USD | — | — | 1.9% | |
BIOABioAge Labs, Inc. | Mar 2026 | $1.16M USD | -80.7% | +151.2% | 0.3% |
| Dec 2025 | $773K USD | — | — | 0.3% | |
| Mar 2026 | $634K USD | — | — | 0.2% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding BIOA) | — | +101.4% | -65.9% | 1.5% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.